2021 CMSC Annual Meeting

Tag: (1)Department of Neurology

Poster-Symptom Management

Systematic Review of Real-World Evidence on the Effect of Nabiximols on Pain and Sleep Impairment in Persons with MS (PwMS) Experiencing Spasticity

Background: Recent data have shown that PwMS may use cannabis to treat their complex symptoms, most frequently spasticity, pain, and...

Read More

Poster-Programs

Knowledge, Skills, and Confidence of Healthcare Professionals Participating in the Echo MS Program

Background: ECHO MS is a videoconference-based education and case-consultation program that seeks to expand MS expertise. In Fall 2020, the...

Read More

Poster-Non-imaging Biomarkers

Cerebrospinal Fluid Protein Is Higher in Males with Multiple Sclerosis: Results from an International Multicenter Cohort

Background: Sex has a differential effect on MS disease severity. Males tend to have a more severe clinical course and …...

Read More

Poster-Epidemiology and Genetics

Motor Impairment in Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)

Background: NARCRMS is a longitudinal registry studying the course of MS in the disease-modifying era. Objectives: To examine motor...

Read More

Poster-Disease-modifying Therapy

Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 Experience–US Study

Background: Diroximel fumarate (DRF) is an oral fumarate approved in the United States (US) for relapsing multiple sclerosis (MS). DRF...

Read More

Poster-Disease-modifying Therapy

Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data

Background: The efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. This analysis provides the first account...

Read More

Poster-Disease-modifying Therapy

Natalizumab: Management and Safety during the COVID-19 Pandemic

Background: MS patients treated with monoclonal antibodies have an increased risk of infections. Natalizumab (NTZ) is a monoclonal antibody...

Read More

Poster-Disease-modifying Therapy

Immunoglobulin Kinetics and Infection Risk after Long-Term Inebilizumab Treatment for Neuromyelitis Optica Spectrum Disorder

Background: Long-term use of B-cell depleting monoclonal antibodies is associated with reduced immunoglobulin (Ig) levels that can...

Read More

Poster-Disease-modifying Therapy

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...

Read More

Poster-Case Reports / Case Series

Multiple Sclerosis in a Patient with Neurofibromatosis Type-1

Background: The association of multiple sclerosis (MS) and neurofibromatosis type 1 (NF1) has been rarely reported. Objectives: To report a...

Read More